Fully automated random-access system for monitoring of therapeutic monoclonal antibodies

⁠⁠⁠NSW Health Pathology currently provides services for measurement of monoclonal therapeutics at the Liverpool hospital site. NSW Health Pathology are looking for improved capabilities and service delivery to facilitate services into the future. Current ELISA (enzyme linked immunosorbent assay) technology is batched and for the less common drugs, this results in delays in results impacting on the ability of clinicians to make timely decisions.

We are looking for a fully automated system for testing of infliximab, adalimumab, and a range of other therapeutic monoclonal drug levels and antibodies against these drugs. A random-access solution which can process at least 100 samples in 8 hours is required